Menu Search
Equities

Oramed Pharmaceuticals Inc

OJU1:DUS

Oramed Pharmaceuticals Inc

Actions
  • Price (EUR)2.12
  • Today's Change-0.041 / -1.89%
  • Shares traded999.00
  • 1 Year change+20.87%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Oramed Pharmaceuticals Inc had revenues fall -50.43% from 2.70m to 1.34m, though the company grew net income from a loss of 36.56m to a gain of 5.53m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets12.19%
Return on equity12.70%
Return on investment12.29%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Oramed Pharmaceuticals Inc fell by 31.41m. Cash Flow from Financing totalled 51.98m or 3,878.96% of revenues. In addition the company used 10.30m for operations while cash used for investing totalled 73.04m.
Cash flow per share0.5079
Price/Cash flow per share4.50
Book value per share4.36
Tangible book value per share4.36
More ▼

Balance sheet in USDView more

Oramed Pharmaceuticals Inc uses little or no debt in its capital structure.
Current ratio41.06
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.